quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 23, 2026

Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions

View original at finance.yahoo.com
Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Snowflake is a company that is growing fast and holding a lot of cash, while spending remains high and seeing significant increase in customer revenue

    60% confidence

  • The valuation narrative could crack if competitive pressure from Databricks intensifies or if Snowflake's losses and stock based compensation continue to weigh on sentiment

    60% confidence

  • Snowflake's fair value is $78.83 per share based on the most followed valuation narrative

    60% confidence

  • Snowflake's DCF model fair value is $236.22 per share, implying the stock is trading at a 28.9% discount

    60% confidence

  • Snowflake is 113.1% overvalued based on most popular narrative

    60% confidence

Data points we hold from this source

Snowflake Inc. · fair value dcf236.22 USD
Snowflake Inc. · fair value narrative78.83 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions — Source | Via News | pt.VIA.NEWS